(Q35583405)

9 August 2017

1 reference

title

Clinical Experience with Trastuzumab (Herceptin) (English)

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

author name string

Charles L. Vogel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616939

1 April 2024

Sandra X. Franco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616939

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14616939

1 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

https://doi.org/10.1046/j.1524-4741.2003.09602.x

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616939

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1524-4741.2003.09602.x

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1524-4741.2003.09602.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

1 reference

9 August 2017

volume

9

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

452-462

1 reference

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Hormone replacement therapy (HRT): indications and side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1524-4741.2003.09602.X

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Cisplatin as first-line therapy for metastatic breast cancer

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 April 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

33

11

143

Bangemann N

2000

1 reference

https://api.crossref.org/works/10.1046/J.1524-4741.2003.09602.X

1 April 2024

Identifiers

1 reference

9 August 2017

1 reference